Psykey, Inc. (CEOS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Psykey, Inc. (CEOS) with AI Score 68/100 (Buy). Psykey, Inc. focuses on researching, developing, and commercializing entheogenic, adaptogenic, and nootropic ingredients. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Psykey, Inc. (CEOS) Healthcare & Pipeline Overview
Psykey, Inc., formerly CeCors, Inc., operates in the healthcare sector, focusing on entheogenic and adaptogenic ingredients for functional products. The company develops technologies for targeted delivery of entheogen-based therapeutics and offers retail products like mushroom-infused beverages and supplements, positioning itself in the emerging psychedelic market.
Investment Thesis
Psykey, Inc. presents a speculative investment opportunity within the emerging psychedelic therapeutics and functional ingredients market. The company's focus on developing technologies for targeted delivery of entheogen-based therapeutics could be a key value driver, contingent on successful research and regulatory approvals. With a market capitalization of $0.00B and a negative P/E ratio of -2.38, the company's financial performance is currently weak, indicated by a negative profit margin of -5.6%. However, a high gross margin of 99.6% suggests potential for profitability if sales volume increases. Key growth catalysts include successful product launches and advancements in their therapeutic technologies. The investment thesis hinges on Psykey's ability to capitalize on the growing interest in psychedelic medicine and functional foods.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E Ratio of -2.38 reflects current losses, suggesting the company is in a growth phase and not yet profitable.
- Gross Margin of 99.6% demonstrates strong pricing power and efficient cost management in its product lines.
- Profit Margin of -5.6% highlights the need for improved operational efficiency and increased sales to achieve profitability.
- Beta of 0.63 suggests the stock is less volatile than the overall market, potentially offering some stability in a turbulent sector.
Competitors & Peers
Strengths
- Focus on emerging markets of entheogenic and adaptogenic ingredients.
- Development of innovative delivery technologies.
- Diverse product lines including functional beverages and supplements.
- High gross margin.
Weaknesses
- Limited market capitalization.
- Negative profit margin.
- Reliance on research and development for future growth.
- Limited brand recognition.
Catalysts
- Upcoming: Potential regulatory approvals for entheogen-based therapeutics could significantly boost investor confidence and market valuation.
- Ongoing: Expansion of product lines and market reach in the functional food and beverage sector.
- Ongoing: Strategic partnerships with research institutions and pharmaceutical companies to accelerate development and commercialization.
Risks
- Potential: Regulatory hurdles and uncertainty surrounding entheogen-based products could delay or prevent commercialization.
- Potential: Intense competition in the functional food and psychedelic markets could limit market share and profitability.
- Ongoing: Limited market capitalization and negative profit margin pose financial sustainability risks.
- Ongoing: Dependence on research and development for future growth exposes the company to technological and clinical trial risks.
Growth Opportunities
- Expansion of Product Lines: Psykey can capitalize on the growing demand for functional foods and beverages by expanding its product lines to include a wider range of mushroom-infused products and supplements. The global functional food market is projected to reach $267.92 billion by 2027, offering a substantial opportunity for Psykey to increase its market share through innovative product development and targeted marketing campaigns. Timeline: 1-2 years.
- Development of Entheogen-Based Therapeutics: Psykey's research and development efforts in entheogen-based therapeutics could lead to the development of novel treatments for mental health disorders. The psychedelic therapeutics market is projected to reach $10.75 billion by 2027, presenting a significant growth opportunity for Psykey if it can successfully navigate regulatory approval processes and commercialize its therapeutic technologies. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: Psykey can accelerate its growth by forming strategic partnerships with research institutions, pharmaceutical companies, and distribution networks. Collaborations can provide access to new technologies, funding, and market channels, enabling Psykey to expand its reach and accelerate the development and commercialization of its products. Timeline: Ongoing.
- Geographic Expansion: Psykey can expand its geographic presence by targeting new markets in North America, Europe, and Asia. The global market for functional foods and psychedelic therapeutics is growing rapidly, offering opportunities for Psykey to establish a presence in new regions and increase its customer base. Timeline: 2-3 years.
- Intellectual Property Protection: Psykey can strengthen its competitive advantage by securing intellectual property protection for its innovative formulations and technologies. Patents and trademarks can provide exclusive rights to its products and processes, preventing competitors from replicating its offerings and enhancing its market position. Timeline: Ongoing.
Opportunities
- Expansion into new geographic markets.
- Strategic partnerships with research institutions and pharmaceutical companies.
- Increasing consumer demand for functional foods and alternative therapies.
- Potential for regulatory approval of entheogen-based therapeutics.
Threats
- Intense competition in the functional food and psychedelic markets.
- Regulatory hurdles and uncertainty surrounding entheogen-based products.
- Potential for adverse side effects from entheogenic ingredients.
- Fluctuations in raw material costs.
Competitive Advantages
- Proprietary formulations of entheogenic, adaptogenic, and nootropic ingredients.
- Development of targeted delivery technologies for entheogen-based therapeutics.
- Early mover advantage in the emerging psychedelic market.
About CEOS
Psykey, Inc., founded in 2002 and based in Toronto, Canada, is a healthcare company engaged in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients. These ingredients are used in their functional product lines, which aim to improve and optimize life. The company also develops technologies focused on the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the burgeoning psychedelic market. Psykey's retail offerings include functional mushroom coffees and teas, oral supplements, and single-serve drink mixes. Formerly known as CeCors, Inc., the company rebranded as Psykey, Inc. in August 2021, signaling its strategic shift towards psychedelic and functional ingredients. This transformation reflects the company's commitment to innovation in the health and wellness sector, particularly in areas related to mental health and cognitive enhancement. Psykey's focus on research and development aims to create novel therapeutic solutions and consumer products that leverage the potential benefits of entheogens and adaptogens.
What They Do
- Researches and develops entheogenic ingredients.
- Researches and develops adaptogenic ingredients.
- Researches and develops nootropic ingredients.
- Formulates functional product lines.
- Develops technologies for targeted delivery of entheogen-based therapeutics.
- Offers functional mushroom coffees and teas.
- Offers oral supplements.
- Offers single-serve drink mixes.
Business Model
- Develops and sells functional food and beverage products containing mushroom extracts and other adaptogens.
- Researches and develops technologies for the delivery of entheogen-based therapeutics.
- Generates revenue through direct-to-consumer sales and partnerships with retailers.
Industry Context
Psykey, Inc. operates within the rapidly evolving market for functional foods and psychedelic therapeutics. The industry is experiencing increased interest in alternative treatments for mental health and wellness, driving demand for products containing entheogenic and adaptogenic ingredients. This market is characterized by intense competition, with numerous companies vying for market share. Psykey's focus on research and development aims to differentiate itself through innovative formulations and targeted delivery technologies. The company's success will depend on its ability to navigate regulatory hurdles and establish a strong brand presence in a competitive landscape.
Key Customers
- Health-conscious consumers seeking functional food and beverage products.
- Individuals interested in the potential benefits of adaptogens and nootropics.
- Patients seeking alternative treatments for mental health disorders (future).
Financials
Chart & Info
Psykey, Inc. (CEOS) stock price: Price data unavailable
Latest News
No recent news available for CEOS.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CEOS.
Price Targets
Wall Street price target analysis for CEOS.
MoonshotScore
What does this score mean?
The MoonshotScore rates CEOS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Maher
CEO
Michael Maher is the CEO of Psykey, Inc., leading a team of six employees. His background includes experience in managing and developing companies within the health and wellness sector. Maher's expertise lies in identifying emerging market trends and translating them into viable business strategies. He has a track record of driving innovation and growth in companies focused on functional ingredients and therapeutic solutions. Maher's leadership is focused on advancing Psykey's research and development efforts and expanding its market presence.
Track Record: Under Michael Maher's leadership, Psykey, Inc. has focused on developing technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics. He oversaw the rebranding from CeCors, Inc. to Psykey, Inc. in August 2021, signaling a strategic shift towards the psychedelic market. Maher's tenure has been marked by efforts to expand the company's product lines and establish partnerships within the industry.
CEOS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Psykey, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier involves higher risks due to the potential for limited information and liquidity compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and financial reporting requirements.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Information asymmetry due to limited public information.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory compliance.
- Determine the company's capital structure and funding sources.
- Monitor the company's trading volume and price volatility.
- Consult with a qualified financial advisor.
- Company's history of operations since 2002.
- Focus on research and development of innovative products.
- Presence in the emerging market for functional foods and psychedelic therapeutics.
- Management team with experience in the health and wellness sector.
CEOS Healthcare Stock FAQ
What does Psykey, Inc. do?
Psykey, Inc. is a healthcare company that researches, develops, and commercializes entheogenic, adaptogenic, and nootropic ingredients for functional product lines. They focus on technologies for targeted delivery of entheogen-based therapeutics, aiming to improve mental health and cognitive function. Their retail products include functional mushroom coffees and teas, oral supplements, and single-serve drink mixes, positioning them in the emerging psychedelic and functional food markets. The company seeks to capitalize on the growing interest in alternative treatments and wellness solutions.
What do analysts say about CEOS stock?
As of March 17, 2026, there is no available analyst coverage for CEOS stock. Given its OTC Other listing and micro-cap status, the stock may not be actively tracked by major research firms. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include market capitalization, P/E ratio, gross margin, and profit margin.
What are the main risks for CEOS?
The main risks for Psykey, Inc. include regulatory uncertainty surrounding entheogen-based products, intense competition in the functional food and psychedelic markets, limited market capitalization, and negative profit margin. The company's dependence on research and development for future growth exposes it to technological and clinical trial risks. Additionally, its OTC listing on the OTC Other tier carries inherent risks related to liquidity, transparency, and regulatory oversight. Investors should carefully consider these factors before investing in CEOS.
What are the key factors to evaluate for CEOS?
Psykey, Inc. (CEOS) currently holds an AI score of 68/100, indicating moderate score. Key strength: Focus on emerging markets of entheogenic and adaptogenic ingredients.. Primary risk to monitor: Potential: Regulatory hurdles and uncertainty surrounding entheogen-based products could delay or prevent commercialization.. This is not financial advice.
How frequently does CEOS data refresh on this page?
CEOS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CEOS's recent stock price performance?
Recent price movement in Psykey, Inc. (CEOS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on emerging markets of entheogenic and adaptogenic ingredients.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CEOS overvalued or undervalued right now?
Determining whether Psykey, Inc. (CEOS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CEOS?
Before investing in Psykey, Inc. (CEOS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 17, 2026.
- OTC market data may be limited or inconsistent.
- Analyst coverage may not be available for this stock.